Market Overview

Mid-Afternoon Market Update: NASDAQ Down 1.1%; Handy & Harman Shares Spike Higher


Toward the end of trading Tuesday, the Dow traded down 0.15 percent to 21,378.09 while the NASDAQ declined 1.10 percent to 6,178.40. The S&P also fell, dropping 0.41 percent to 2,429.16.

Leading and Lagging Sectors

Energy shares rose by 0.46 percent in the US market on Tuesday. Top gainers in the sector included Zion Oil & Gas, Inc. (NASDAQ: ZN), CARBO Ceramics Inc. (NYSE: CRR), and SunCoke Energy Inc (NYSE: SXC).

In trading on Tuesday, technology shares fell by 1.27 percent. Meanwhile, top losers in the sector included Camtek LTD. (NASDAQ: CAMT), down 14 percent, and iRobot Corporation (NASDAQ: IRBT), down 9 percent.

Top Headline

Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) was slapped with a $2.7 billion fine from the European Union.

The EU's antitrust body confirmed in a press release it has fined Google's parent company $2.7 billion for what it believes is unfair treatment of its own search services over its rivals. As a market leader in internet search, Google is giving an unfair and illegal advantage to its own comparison shopping service.

Equities Trading UP

Handy & Harman Ltd (NASDAQ: HNH) shares shot up 9 percent to $31.15 after Steel Partners Holdings LP (NYSE: SPLP) agreed to acquire the remaining outstanding shares of Handy & Harman.

Shares of Chicago Bridge & Iron Company N.V. (NYSE: CBI) got a boost, shooting up 32 percent to $18.97. Delaware Supreme Court ruled in favor of Chicago Bridge & Iron in dispute with Westinghouse Electric, Reuters reported.

Avenue Therapeutics Inc (NASDAQ: ATXI) shares were also up, gaining 33 percent to $7.95. Avenue Therapeutics priced its 5.5 million share IPO at $6.00 per share.


Equities Trading DOWN

Alder Biopharmaceuticals Inc (NASDAQ: ALDR) shares dropped 23 percent to $14.32 following the inconclusive results from its Promise 1 Phase 3 trial of Eptinezumab, the company's lead product for migraine prevention. Although the trial met primary and secondary endpoints, the Street is worried that several notable parts of the data were concerning, namely the statistical significance for the 100mg dose and against Placebo.

Shares of Ra Pharmaceuticals Inc (NASDAQ: RARX) were down 18 percent to $18.11 after the company issued updates on Phase 2 trial of RA101495.

Xenon Pharmaceuticals Inc (NASDAQ: XENE) was down, falling around 21 percent to $3.00 after the company reported results from Phase II study of TV-45070 in patients with PHN. The study did not meet primary and secondary endpoints.


In commodity news, oil traded up 1.82 percent to $44.17 while gold traded up 0.15 percent to $1,248.30.

Silver traded up 0.02 percent Tuesday to $16.635, while copper rose 0.80 percent to $2.6595.


European shares closed lower today. The eurozone’s STOXX 600 declined 0.79 percent, the Spanish Ibex Index fell 0.46 percent, while Italy’s FTSE MIB Index dropped 1.01 percent. Meanwhile the German DAX declined 0.78 percent, and the French CAC 40 slipped 0.70 percent while U.K. shares fell 0.17 percent.


The Johnson Redbook Sales Index rose 0.6 percent during the first four weeks of June versus May.

The Conference Board’s consumer confidence index increased to 118.90 in June, versus previous reading of 117.90. Economists expected a reading of 116.90.

The Richmond Fed's manufacturing index rose to 7.00 in June, versus a prior reading of 1.00.

Minneapolis Federal Reserve Bank President Neel Kashkari will speak in Houghton, Michigan at 5:30 p.m. ET.

Posted-In: M&A News Eurozone Commodities Global Intraday Update Markets Movers


Related Articles (ALDR + ATXI)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at